F. Hoffmann-La Roche & Co. was founded in Basel, Switzerland by the 28 year old Fritz Hoffmann-La Roche on October 1, 1896, at a historic time when the industrial revolution was changing the face of Europe. He was among the first to recognise that the industrial manufacture of medicines would be a major advance in the fight against disease.
Throughout our 125-year history, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.
Where are we today?
Today, Roche, headquartered in Basel, Switzerland, operates in more than 150 countries with more than 100 thousand employees.
Roche, focusing on “doing now what patients need next”, explores, develops and offers products and services that will provide significant benefits to patients and healthcare professionals. Roche has an important position in the field of personalized healthcare, as it incorporates all areas of diagnosis, treatment and big data. At Roche, personalized healthcare is a primary focus area, combining science, data, analytics and technology to advance new discoveries and improve patients' lives.
For many years, personalized healthcare meant testing for a disease-related biomarker and providing a targeted treatment. Today, we extend and connect this personalized approach across the patient care continuum to deliver evidence-based, technology-enabled health solutions personalized to each individual.
Today, more than 30 medicines developed by Roche, including life-saving antibiotics, antimalarials and cancer drugs, are on the World Health Organization's List of Essential Medicines.Roche is also ranked as one of the most sustainable companies in the Pharmaceutical Industry in the Dow Jones Sustainability Index (DJSI) for 14 consecutive years.
Today, Roche, one of the world's largest biotechnology companies with its activities in the field of healthcare services and technologies, is positioned not only as a healthcare company that offers diagnostic and treatment solutions, but also as a scientific data and technology company that aims to improve patients’ lives with its structure that enables it to approach healthcare services from a 360-degree perspective.
Roche's main goal is to identify the needs of patients and customers and to offer diagnostic and treatment solutions that can meet their needs. With this aim, we are working to better understand our patients and customers and to create solutions for the needs of the future today.
Within the scope of our corporate activities, we prioritize areas where we know we can make a difference with our experience and where there are unmet needs.
As an innovative healthcare provider, our purpose is to improve the lives of patients and to develop and make available products and services with high medical value.
As a research-oriented company, we benefit from the latest technologies and discoveries while developing our products. As Roche, we allocated 14 billion Swiss francs to research and development in 2022. In this scope, we are among the top 9 R&D investors across all industries, and the number 1 investor in healthcare.
For over 60 years, Roche Pharmaceuticals Turkey has been creating value for the society with a focus of increasing accessibility with developments in science and technology in the field of pharmaceuticals, especially in oncology, hematology, neurology, rheumatology and rare diseases. Today, Roche Pharmaceuticals Turkey, with more than 250 employees, develops the innovative technologies of the future and works to make medical solutions available in the fastest and most reliable way.
Established in 1991 with the aim of becoming one of the leading healthcare companies in Turkey, Roche Diagnostics Turkey improves the patients’ lives with its innovative and advanced technology-based devices for professional and personal use, biochemistry, hormone, genetic, molecular and cancer test portfolio in the fields of Centralised and Point of Care Solutions, Molecular Solutions and Diabetes Care.
In Turkey, Roche will continue to improve the quality of health and life with its global understanding and local creative solutions.
As digitalization takes healthcare practices to a new dimension, personalized diagnostics and treatment, which we define as "Personalized Healthcare" where patients are involved in their own disease management processes, are shaping the healthcare systems of the future. These solutions, which are becoming more widely used with digitalization, also contribute to the development of treatment strategies based on early diagnosis.
Personalized healthcare means utilizing data about a person's unique genetic makeup, lifestyle, individual needs, preferences, experience and emotional state to shape treatment and care decisions. The main aim of the personalized patient journey is to ensure that the patient has access to the right information, early diagnosis and the most appropriate treatment. In this context, Roche, which continues its efforts with the aim of delivering the right treatment in the most accurate way in all disease areas, plays an important role in the field of personalized healthcare services by offering innovative solutions on the path from diagnosis to treatment.
The information provided on this site is not for diagnostic or medical advice, but for informational purposes. If you have or think you have a disease to be treated, consult a specialist physician.
For adverse events related to Roche products,
To contact us about other issues;
Roche Pharma Address: Roche Müstahzarları San A.Ş. Uniq İstanbul Ayazağa Caddesi No:4D/101 34396 Maslak/İstanbul Tel: +90 212 366 90 00
KEP:
Roche Diagnostics Address: Roche Diagnostics Turkey A.Ş. Esentepe Mah. Kırgülü Sk. Metrocity İş Merkezi D Bl. No: 4/5 34394 Şişli /İstanbul; Tel: +90 212 306 06 06
KEP:
Supervisors: Bahar Süral & Naz Kocaoğlu